New cocktail of chemo and immunotherapy aims to tame tough cancers

NCT ID NCT04150640

Recruiting now Disease control Sponsor: University of Wisconsin, Madison Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of three chemotherapy drugs plus immunotherapy as a first treatment for advanced esophageal and gastric cancer. For patients with HER2-positive tumors, the targeted drug trastuzumab is also added. The study aims to see if this mix is more effective and better tolerated than current standard treatments. About 52 participants will be enrolled across multiple sites.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy drugs (5-FU, oxaliplatin, liposomal irinotecan) and immunotherapy (pembrolizumab or nivolumab, plus trastuzumab for HER2-positive tumors)
What this could lead to: If successful, this combination could offer a better-tolerated first-line treatment option for advanced esophageal and gastric cancer, potentially improving response rates.
What could go wrong: This is an early phase 2 trial with only 52 participants, so results may not apply to all patients. The drug combination may cause significant side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL ADENOCARCINOMA GASTRIC ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

University of Wisconsin Carbone Cancer Center
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.